

Information for Vermont Prescribers of Prescription Drugs

LAGEVRIO™ (molnupiravir) Capsules

- This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.
- The prices listed below are Average Wholesale Prices ("AWP") as established and made available to the public by a third party publisher or as calculated from data made available to the public by a third party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
- The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.
- LAGEVRIO has not been approved, but has been authorized for emergency use by the FDA under an Emergency Use Authorization (EUA), for the treatment of adults with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.
- The emergency use of LAGEVRIO is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the FDA Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

Before prescribing LAGEVRIO, please read the accompanying [Fact Sheet for Healthcare Providers](#), including Mandatory Requirements for Administration of LAGEVRIO Under Emergency Use Authorization. The [FDA Letter of Authorization](#) and the [Fact Sheet for Patients and Caregivers](#) are also available.

Price Comparison:

Marketed product and lowest dosage of other products in same therapeutic class.*

| <u>Marketed Product:</u> | <u>Unit Price</u> |
|---|--------------------------|
| LAGEVRIO (EUA) 200 mg Capsule | \$28.50 |
| <u>Other Products:</u> | <u>Unit Price</u> |
| Acyclovir 400 mg Tablet | \$0.23 |
| Acyclovir 200 mg Capsule | \$0.45 |
| Ribavirin 200 mg Capsule & Tablet | \$1.19 |
| Famciclovir 125 mg Tablet | \$1.58 |
| Valacyclovir 500 mg Tablet | \$1.61 |
| Entecavir 0.5 mg Tablet | \$7.33 |
| Valtrex 500 mg Tablet | \$16.11 |
| Valganciclovir HCl 450 mg Tablet | \$29.34 |
| Adefovir Dipivoxil 10 mg Tablet | \$35.80 |
| Baraclude 0.5 mg Tablet | \$54.90 |
| Vemlidy 25 mg Tablet | \$57.66 |
| Hepsera 10 mg Tablet | \$65.21 |
| Valcyte 450 mg Tablet | \$106.08 |
| Symtuza 800 mg-150 mg-200 mg-10 mg Tablet | \$188.68 |

- * Prices shown are for the lowest dosage of each product. Prices for multi-source products have been averaged. Multiple forms of the same product (eg, tabs and caps) have been considered one product, and the prices have been averaged. Chewable forms of the product are not included.

For additional price comparison information, see:
<https://www.merckconnect.com/pricing-disclosures>

For more information about First Databank's Drug Pricing Policy visit below site.
<http://www.fdbhealth.com/policies/drug-pricing-policy/>

Source: First Databank, 02/04/2024. Reprinted with permission by First Databank Inc. All rights reserved. © 2024.